Switzerland · Delayed Price · Currency is CHF Siegfried Holding AG Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition of three sites in the U.S. and Australia expands manufacturing capacity, strengthens supply chain resilience, and positions the company for growth in high-demand drug substance markets. The deal is value-accretive, margin accretive, and enables rapid integration with minimal CapEx.
Fiscal Year 2025
-
Record profitability and margin expansion achieved in 2025, with 4.3% sales growth in local currency and strong cash generation. Strategic acquisitions and robust project inflow support a positive midterm outlook, despite currency headwinds and a pending large contract.
-
Solid H1 2025 results with 1.6% local currency sales growth, EBITDA margin up to 21.6%, and strong cash flow from networking capital optimization. Full-year guidance confirmed, with continued investment in technology, capacity, and selective M&A to drive above-market growth.
Fiscal Year 2024
-
Strong 2024 results with 8%-9% underlying growth, Core EBITDA margin above 22%, and 24% higher Core Net Profit. 2025 guidance targets mid-single-digit growth and continued margin expansion, with robust segment performance, ongoing M&A, and major capacity investments.
-
EVOLVE+ strategy focuses on scaling, technology expansion, and operational excellence to drive growth and margin improvement. Financial guidance confirms continued profitable growth above market, with disciplined capital allocation and strong diversification. Sustainability, digitalization, and tailored customer strategies further strengthen market position.
-
Net sales grew 3.5% in local currencies and core net profit rose 21.8% in H1 2024, with profitability and cash flow both improving. Strategic acquisitions and capacity expansions support a positive outlook, with guidance reaffirmed for low single-digit sales growth and stable margins.